Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex vivo Journal Article


Authors: Atzpodien, J.; Gulati, S. C.; Kwon, J. H.; Kushner, B. H.; Shimazaki, C.; Bührer, C.; Öz, S.; Kolitz, J. E.; Welte, K.; Clarkson, B. D.
Article Title: Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex vivo
Abstract: We studied the ex vivo sensitivity of continuously cultured neuroblastoma cells from 3 different patients towards interleukin-2-induced cell-mediated cytotoxicity. A mean (± SD) target cell lysis (4 h51Cr release) of 49 ± 11, 46 ± 8. And 32 ± 11% in SMS-SAN, LA-N-1, and SK-N-BE2 cell lines, respectively, was achieved when neuroblastoma cells were co-cultured at an effector-to-target (E: T) ratio of 50:1 with peripheral blood mononuclear cells (PBMC) that had been preincubated for 4 days in the presence of recombinant interleukin-2 (rIL-2; 100 U/ml). Under identical conditions, 93 ± 9% of Daudi cells (a standard target for rIL-2-activated killer cells) were lysed. Preincubation of rIL-2-induced PBMC cultures in the presence of irradiated neuroblastoma targets (LA-N-1, SK-N-BE2) resulted in a significant cytolytic augmentation. At E: T ratios of 50:1 and 10:1, day-4 rlL-2/LA-N-1-stimulated PBMC produced 69 ± 7and41 ± 11% lysis of LA-N-1 cells, as compared to 46 ± 8 and 22 ± (mean ± SD) 7% lysis by untargeted PBMC that were preincubated with rIL-2 (100 U/ml) in the absence of LA-N-1 target cells (p < 0.05). Co-incubation of rIL-2-induced PBMC preparations with irradiated LA-N-1 and SK-N-BE2 cells, respectively, did not significantly enhance the cytolytic activity against other neuroblastoma targets and the standard Daudi cell line (p ≥0.3). In summary, our results suggest that cell-mediated cytotoxicity using rIL-2-activated effector cells may be potentially useful in the immunotherapy of human neuroblastoma. © 1988 S. Karger AG, Basel.
Keywords: controlled study; human cell; interleukin 2; cytotoxicity; neuroblastoma; cytotoxicity, immunologic; bone marrow cell; radioisotope; interleukin-2; killer cell; lymphokine activated killer cell; human; female; priority journal; killer cells; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; lymphokine-activated killer cells; target-specific cytotoxicity
Journal Title: Experimental Cell Biology
Volume: 56
Issue: 5
ISSN: 0304-3568
Publisher: S. Karger AG  
Date Published: 1988-01-01
Start Page: 236
End Page: 244
Language: English
DOI: 10.1159/000163486
PUBMED: 3265922
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 6 August 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Brian Kushner
    311 Kushner
  2. Bayard Clarkson
    220 Clarkson
  3. Subhash C. Gulati
    129 Gulati
  4. Karl Welte
    77 Welte
  5. Jonathan E. Kolitz
    21 Kolitz